Estrogen receptor blocker

TERMINATED · PHASE3 · Breast Neoplasms, Neoplasms, Hormone-Dependent

Identical study Biomed 777-CLP-029 did not meet superiority endpoint

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.